OssDsign AB (publ) (OSSD.ST)
SEK 10.08
(0.4%)
SEK 10.08
(0.4%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 4.3 Million SEK | -2.58% |
| 2022 | 4.41 Million SEK | 107.91% |
| 2021 | 2.12 Million SEK | 3.61% |
| 2020 | 2.05 Million SEK | 17.07% |
| 2019 | 1.75 Million SEK | 29.39% |
| 2018 | 1.35 Million SEK | 180.91% |
| 2017 | 482 Thousand SEK | 104.93% |
| 2016 | 235.19 Thousand SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 9.79 Million SEK | 127.65% |
| 2024 Q2 | 10.17 Million SEK | 3.84% |
| 2023 Q4 | 4.3 Million SEK | -54.65% |
| 2023 Q2 | 5.67 Million SEK | 10.22% |
| 2023 FY | 4.3 Million SEK | -2.58% |
| 2023 Q1 | 5.14 Million SEK | 16.52% |
| 2023 Q3 | 9.49 Million SEK | 67.25% |
| 2022 Q4 | 4.41 Million SEK | 6.28% |
| 2022 Q2 | 2.74 Million SEK | -2.21% |
| 2022 FY | 4.41 Million SEK | 107.91% |
| 2022 Q1 | 2.8 Million SEK | 31.95% |
| 2022 Q3 | 4.15 Million SEK | 51.6% |
| 2021 Q3 | 2.66 Million SEK | 10.43% |
| 2021 FY | 2.12 Million SEK | 3.61% |
| 2021 Q4 | 2.12 Million SEK | -20.38% |
| 2021 Q2 | 2.41 Million SEK | 6.06% |
| 2021 Q1 | 2.27 Million SEK | 11.12% |
| 2020 Q2 | 1.87 Million SEK | 2.74% |
| 2020 FY | 2.05 Million SEK | 17.07% |
| 2020 Q3 | 2.22 Million SEK | 18.64% |
| 2020 Q1 | 1.82 Million SEK | 4.34% |
| 2020 Q4 | 2.05 Million SEK | -7.94% |
| 2019 Q3 | 1.23 Million SEK | 4.4% |
| 2019 Q1 | 1.28 Million SEK | -5.32% |
| 2019 FY | 1.75 Million SEK | 29.39% |
| 2019 Q4 | 1.75 Million SEK | 42.09% |
| 2019 Q2 | 1.18 Million SEK | -7.88% |
| 2018 FY | 1.35 Million SEK | 180.91% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q4 | 1.35 Million SEK | 0.0% |
| 2017 FY | 482 Thousand SEK | 104.93% |
| 2016 FY | 235.19 Thousand SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Acarix AB (publ) | 6.83 Million SEK | 37.067% |
| ADDvise Group AB (publ) | 121.2 Million SEK | 96.449% |
| ADDvise Group AB (publ) | 121.2 Million SEK | 96.449% |
| Arcoma AB | 28.02 Million SEK | 84.643% |
| Bactiguard Holding AB (publ) | 29.64 Million SEK | 85.482% |
| BICO Group AB (publ) | 493.1 Million SEK | 99.127% |
| Boule Diagnostics AB (publ) | 62.4 Million SEK | 93.103% |
| CellaVision AB (publ) | 126.03 Million SEK | 96.585% |
| Clinical Laserthermia Systems AB (publ) | 6.11 Million SEK | 29.616% |
| Chordate Medical Holding AB (publ) | 1.77 Million SEK | -143.037% |
| C-Rad AB (publ) | 64.09 Million SEK | 93.285% |
| Duearity AB (publ) | 4.15 Million SEK | -3.486% |
| Dignitana AB (publ) | 7.41 Million SEK | 41.94% |
| Episurf Medical AB (publ) | 3.7 Million SEK | -16.324% |
| Getinge AB (publ) | 6.41 Billion SEK | 99.933% |
| Scandinavian Real Heart AB (Publ) | -1.68 Million SEK | 355.677% |
| Iconovo AB (publ) | -4.86 Million SEK | 188.523% |
| Integrum AB (publ) | 22.36 Million SEK | 80.753% |
| Luxbright AB (publ) | 8000.00 SEK | -53700.0% |
| Mentice AB (publ) | 14.1 Million SEK | 69.484% |
| Paxman AB (publ) | 19.99 Million SEK | 78.479% |
| Promimic AB (publ) | 330 Thousand SEK | -1204.242% |
| Qlife Holding AB (publ) | 7.29 Million SEK | 40.976% |
| SciBase Holding AB (publ) | 11.91 Million SEK | 63.89% |
| ScandiDos AB (publ) | 22.69 Million SEK | 81.031% |
| Sectra AB (publ) | 36.59 Million SEK | 88.237% |
| Sedana Medical AB (publ) | 42.97 Million SEK | 89.985% |
| Senzime AB (publ) | 20.34 Million SEK | 78.84% |
| SpectraCure AB (publ) | 1.00 SEK | -430399900.0% |
| Stille AB | 66.55 Million SEK | 93.533% |
| Vitrolife AB (publ) | 413 Million SEK | 98.958% |
| Xvivo Perfusion AB (publ) | 141.6 Million SEK | 96.961% |